Table 5.
Renal function assessments
| Parameter | IR‐Tac (N = 30) | ER‐Tac (N = 30)a | LCPT (N = 30)a | Treatment effect p‐valueb |
|---|---|---|---|---|
| Serum creatinine (mg/dL), mean (SD) | 1.28 (0.23) | 1.30 (0.29) | 1.28 (0.26) | 0.961 |
| 24 h urine total volume (mL), mean (SD) | 3019 (1312) | 3160 (2831) | 3335 (2616) | 0.873 |
| 24 h creatinine clearance, calculated (mL/min), mean (SD) | 77 (32) | 74 (33) | 76 (32) | 0.929 |
| eGFR (mL/min/1.73 m2) | ||||
| Non–African Americans, mean (SD) |
n = 23 61 (19.4) |
n = 23 61 (20.4) |
n = 22 63 (20.1) |
0.964 |
| African Americans, mean (SD) |
n = 7 72 (17.7) |
n = 6 71 (19.0) |
n = 7 71 (20.6) |
0.981 |
ER‐Tac, extended‐release tacrolimus; IR‐Tac, immediate‐release tacrolimus; LCPT, once‐daily, MeltDose tacrolimus; eGFR, glomerular filtration rate, estimated (mL/min/1.73 m); SD, standard deviation.
a
N = 29 for ER‐Tac group for 24‐h creatinine clearance; N = 29 for eGFR for LCPT.
b
p‐value from one‐way ANOVA with main effect of treatment.